

Innovative partnerships for innovative medicines

14/09/2012



Marta Gómez Quintanilla
Health & IMI Spanish Representative
IMI States Representatives Group vice-Chair
Joint Programming on Neurodegeneration Research MB Member
EU's R&D Framework Programme Department

INDEX

- Statistics & Analysis
- Conclusions



Available online



GENERAL
2007-2010



SALUD & IMI
2011



SALUD & IMI
2012

Provisional ES - IMI 2008-2010



RESULTADOS PARTICIPACIÓN ESPAÑOLA EN IMI Acumulado 2007- 2012. Datos provisionales.

ES Proposal participation (2nd stage)	# ES # Coordinated ES Funding ES, M€	19 1 10,5
ES Results	Financed ES, # (%) Coordinated ES, # (%)	19 (63,3%) 1 (3,3%)
ES Entities	Entities with funded projects (Companies / % SME*)	25 (6, 66,7%)
ES Funding	M€ % UE-27 (% del total)	10,5 3,7% (3,5%)
ES Ranking		8ª

* PYME: empresas < 250 empleados


** En las convocatorias en dos fases sólo se considera la segunda fase de la evaluación

IMI Results




Call IMI	España (M€)	Total (M€)	(%UE-27)
IMI_Call_2008_1	7,0	109,6	6,90%
IMI_Call_2009_1	1,8	80,7	2,34%
IMI_Call_2010_1	1,7	111,8	1,62%
Total	10,5	302,1	3,71%

Statistics




* ES 8 position
* UK, DE & FR = 53% Funding

Statistics




Statistics




participations
≠
Funding

ES Funding





Cataluña= 67%
Cataluña + Madrid= 90%



OPIs= 43%
OPIs + Asoc= 74%

ES Funding



Big differences, specially in companies participation and SMEs

Statistics

30/08/2012		CLOSED			
Call #		1st Call	2nd Call	3rd Call	Partial results
Data*		Official data			
Call text	Publication date	30/04/2008	27/11/2009	22/10/2010	
	Closing date (2nd)	20/01/2009	28/06/2010	15/06/2011	
	IMI funding (M€)	122,7	75,0	114,0	311,7
	EFPIA in kind (M€)	172,5	75,0	114,0	361,5
	TOTAL	295,2	150,0	228,0	673,2
	Call topics	18	9	7	34
1st stage	Expressions of interest	134	124	32	290
	Participants	1.294	1.118	433	2.845
	EoIs/topic	7,4	13,7	4,6	8,5
Results after 2nd stage**	Funded Projects	15***	8****	7	30
	Project Total Cost	287,6	169,5	220,1	677,2
	Project Total funding	109,6	80,7	111,8	302,1
	Success rate	11,2%	7,3%	21,9%	10,3%
	ES in projects (%)	12 (80%)	3 (38%)	4 (57%)	19 (63%)
	ES entities: EFPIA + no EFPIA (SME)	2 + 15 (3)	1 + 5 (0)	3 + 3 (0)	3 + 22 (3)
	ES participations	28	6	6	40
	ES M€ (% UE27)	7,0 (6,9%)	1,8 (2,3%)	1,7 (1,6%)	10,5 (3,7%)
	ES position (funding)	5°	10°	12°	8°

* Data based on information provided by IMI-JU office

** Unless otherwise specified, ES data includes EFPIA and non EFPIA entities

*** 3 proposals failed in 2nd stage



**** 2 proposals merged in 2nd stage

(17/09/2012)

Statistics: Calls


30/08/2012		CLOSED						OPEN			TOTAL	
Call #		1st Call	2nd Call	3rd Call	Partial results	4th Call	5th Call	6th Call	7th Call	ENSO		
Data*		Official data				Estimations						
Call text	Publication date	30/04/2008	27/11/2009	22/10/2010		18/07/2011	06/03/2012	24/05/2012	17/07/2012	21/08/2012		
	Closing date (EoI)	15/07/2008	08/01/2010	11/01/2011	18/10/2011	16/05/2012	09/07/2012	09/10/2012				
	Closing date (Full)	20/01/2009	28/06/2010	15/06/2011	13/03/2012	13/09/2012	10/10/2012	xx/03/2013	30/9 & 15/12			
	IMI funding (M€)	122,7	75,0	114,0	311,7	105,0	80,0	109,0	13,0	5,4		624
	EFPIA in kind (M€)	172,5	75,0	114,0	361,5	105,0	89,0	114,7	13,0	5,4	689	
	TOTAL	295,2	150,0	228,0	673,2	210,0	169,0	223,7	26,0	10,8	1.313	
Call topics		18	9	7	34	7 (9)	2	2 (3)	2	-	38	

* Data based on information provided by IMI-JU office



Statistics: Participation

30/08/2012		CLOSED			
Call #		1st Call	2nd Call	3rd Call	Partial results
Data*		Official data			
Call text	Publication date	30/04/2008	27/11/2009	22/10/2010	
	Closing date (2nd)	20/01/2009	28/06/2010	15/06/2011	
	IMI funding (M€)	122,7	75,0	114,0	311,7
	EFPIA in kind (M€)	172,5	75,0	114,0	361,5
	TOTAL	295,2	150,0	228,0	673,2
	Call topics	18	9	7	34
1st stage	Expressions of interest	134	124	32	290
	Participants	1.294	1.118	433	2.845
	EoIs/topic	7,4	13,7	4,6	8,5



* Data based on information provided by IMI-JU office

** Unless otherwise specified, ES data includes EFPIA and non EFPIA entities

*** 3 proposals failed in 2nd stage


**** 2 proposals merged in 2nd stage

(17/09/2012)

Statistics: Results

30/08/2012		CLOSED			
Call #		1st Call	2nd Call	3rd Call	Partial results
Data*		Official data			
Call text	Publication date	30/04/2008	27/11/2009	22/10/2010	
	Closing date (2nd)	20/01/2009	28/06/2010	15/06/2011	
	IMI funding (M€)	122,7	75,0	114,0	
	EFPIA in kind (M€)	172,5	75,0	114,0	361,5
	TOTAL	295,2	150,0	228,0	673,2
	Call topics	18	9	7	34

Results after 2nd stage**	Funded Projects	15***	8****	7	30
	Project Total Cost	287,6	169,5	220,1	677,2
	Project Total funding	109,6	80,7	111,8	302,1
	Success rate	11,2%	7,3%	21,9%	10,3%
	ES in projects (%)	12 (80%)	3 (38%)	4 (57%)	19 (63%)
	ES entities: EFPIA + no EFPIA (SME)	2 + 15 (3)	1 + 5 (0)	3 + 3 (0)	3 + 22 (3)
	ES participations	28	6	6	40
	ES M€ (% UE27)	7,0 (6,9%)	1,8 (2,3%)	1,7 (1,6%)	10,5 (3,7%)
	ES position (funding)	5°	10°	12°	8°



* Data based on information provided by IMI-JU office

** Unless otherwise specified, ES data includes EFPIA and non EFPIA entities


*** 3 proposals failed in 2nd stage

**** 2 proposals merged in 2nd stage


(17/09/2012)

Statistics: Results

30/08/2012		CLOSED			
Call #		1st Call	2nd Call	3rd Call	Partial results
Data*		Official data			
Call text	Publication date	30/04/2008	27/11/2009	22/10/2010	
	Closing date (2nd)	20/01/2009	28/06/2010	15/06/2011	
	IMI funding (M€)	122,7	75,0	114,0	
	EFPIA in kind (M€)	172,5	75,0	114,0	361,5
	TOTAL	295,2	150,0	228,0	673,2
Call topics		18	9	7	34



Results after 2nd stage**	Funded Projects	15***	8****	7	30
	Project Total Cost	287,6	169,5	220,1	677,2
	Project Total funding	109,6	80,7	111,8	302,1
	Success rate	11,2%	7,3%	21,9%	10,3%
	ES in projects (%)	12 (80%)	3 (38%)	4 (57%)	19 (63%)
	ES entities: EFPIA + no EFPIA (SME)	2 + 15 (3)	1 + 5 (0)	3 + 3 (0)	3 + 22 (3)
	ES participations	28	6	6	40
	ES M€ (% UE27)	7,0 (6,9%)	1,8 (2,3%)	1,7 (1,6%)	10,5 (3,7%)
	ES position (funding)	5°	10°	12°	8°



* Data based on information provided by IMI-JU office


** Unless otherwise specified, ES data includes EFPIA and non EFPIA entities

*** 3 proposals failed in 2nd stage


**** 2 proposals merged in 2nd stage

(17/09/2012)


ES Results (compared with health calls)



ES Results (compared with health calls)



ES Results (compared with health calls)



Tendency

	30/08/2012	CLOSED					OPEN				TOTAL
Call #		1st Call	2nd Call	3rd Call		4th Call	5th Call	6th Call	7th Call	ENSO	
Data*		Official data				Estimations					
Call text	Publication date	30/04/2008	27/11/2009	22/10/2010	Partial results	18/07/2011	06/03/2012	24/05/2012	17/07/2012	21/08/2012	
	Closing date (EoI)	15/07/2008	08/01/2010	11/01/2011		18/10/2011	16/05/2012	09/07/2012	09/10/2012		
	Closing date (Full)	20/01/2009	28/06/2010	15/06/2011		13/03/2012	13/09/2012	10/10/2012	xx/03/2013	30/9 & 15/12	
	IMI funding (M€)	122,7	75,0	114,0	311,7	105,0	80,0	109,0	13,0	5,4	624
	EFPIA in kind (M€)	172,5	75,0	114,0	361,5	105,0	89,0	114,7	13,0	5,4	689
	TOTAL	295,2	150,0	228,0	673,2	210,0	169,0	223,7	26,0	10,8	1.313
	Call topics	18	9	7	34	7 (9)	2	2 (3)	2	-	38
	M€/topic	16	17	33	20	30	85	112	13		41
* Data based on information provided by IMI-JU office											

* Data based on information provided by IMI-JU office

- Project budget gets bigger
- ~34% funding to be committed
- Non EU (EFPIA) participation increasing (new rules).
- From annual calls (2008-2011) to monthly calls (2012-2013) -> overlapping in opening and deadlines, management gets complicated.

IMI Calls: Publication & Deadlines

July

17 - Publication IMI-Call 7

August

21 - Publication IMI-Call-ENSO

September

13 - Deadline IMI-Call 5 (2nd stage)

30 - Deadline IMI-Call-ENSO (1st cut-off day)

¿? - Publication IMI-Call 8

October

9 - Deadline IMI-Call 7 (1st stage)

10 - Deadline IMI-Call 6 (2nd stage)

¿? - Publication IMI-Call 9

November

December

15 - Deadline IMI-Call-ENSO (2nd cut-off day)

At least 6 IMI calls
OPEN
in 6 months



IMI & Health Calls: Publication & Deadlines

July

- 10 - Publication HEALTH-2013-INNO1
- 10 - Publication HEALTH-2013-INNO2
- 17 - Publication IMI-Call 7

August

- 21 - Publication IMI-Call-ENSO

September

- 13 - Deadline IMI-Call 5 (2nd stage)
- 14 - **TODAY**
- 25 - Deadline HEALTH-2013-INNO2 (1st stage)
- 30 - Deadline IMI-Call-ENSO (1st cut-off day)
- ¿? - Publication IMI-Call 8

October

- 2 - Deadline HEALTH-2013-INNO1 (1st stage)
- 9 - Deadline IMI-Call 7 (1st stage)
- 10 - Deadline IMI-Call 6 (2nd stage)
- ¿? - Publication IMI-Call 9

November

December

- 11 - Deadline HEALTH-2013-INNO2 (2nd stage)
- 15 - Deadline IMI-Call-ENSO (2nd cut-off day)



7th Call for proposals

- Building a sustainable framework for rapid assessment of vaccination impact in Europe
- New approaches to effectiveness research

Launch date: 17 July 2012

ENSO - IMI Call for proposals to explore new scientific opportunities in ongoing IMI JU collaborative projects 2012/2013

Launch date: 21 August 2012

8th Call for proposals

- Combating Antibiotic Resistance: NewDrugForBadBugs: Topic 1C (work packages 6 and 7) of Topic 1: Innovative Trial Design & Clinical Development

Tentative launch date: September 2012

9th Call for proposals

- Combination therapy development
- Taxonomy of human diseases
- Web-based data mining for medical insights
- Comprehensive induced pluripotent stem (iPS) cells strategy for Europe
- Discovery and development of new drugs combating Gram - negative infections (Topic 3 of the programme Combating Antibiotic Resistance: NewDrugForBadBugs)

Tentative launch date: October 2012

All information regarding future IMI Call topics is indicative and subject to change. Final information about the IMI's future Calls will be communicated after approval by the IMI Governing Board.

Current situation

General

- Economic crisis
- Health sector strongly affected
- Pharma companies closing EU research&innovation units

IMI

- Tendency to bigger projects
- Some projects NO pre-competitive
- Increase in outside EU participation (as EFPIA contribution in kind)
- Big % of budget to be committed in last years -> Calls every month

Points to reflect: now & for the future

- Open and competitive calls scheme

Coherent planning & enough time to prepare proposals

- European Union Industrial Competitiveness

- Others invited to contribute, but EU funding = EU industry contribution
- The potential of non-SME/non-EFPIA companies is underused

- Strategic Research Agenda

Focus on pre-competitive research -> still many gaps in the SRA for EU

- Future of IMI

Considering problems identified now & in line with EU needs.

Public consultation:

http://ec.europa.eu/research/consultations/life_science_h2020/consultation_en.htm

Consultation on plans for a public-private partnership in life sciences research and innovation - Windows Internet Explorer

http://ec.europa.eu/research/consultations/life_science_h2020/consultation_en.htm

Archivo Edición Ver Favoritos Herramientas Ayuda

Favoritos Nueva pestaña 0110 - Lior - Gypsy Girl Sitios sugeridos Galería de Web Slice

Consultation on plans for a public-private partne...

A-Z Index | Sitemap | About this site | FAQ | What's New | Legal notice | Contact | Search English (en)

 RESEARCH & INNOVATION

Title

Consultation on plans for a public-private partnership in life sciences research and innovation under Horizon 2020

Policy field(s)

Research

Target group(s)

All citizens and organisations are welcome to contribute to this consultation. Contributions are particularly sought from companies, organisations and researchers active in life sciences research and innovation.

implemented through public-private partnerships (PPPs). Selection of PPPs will be based on a set of clearly defined criteria, including the added value of action at Union level, the scale of impact on industrial competitiveness, sustainable growth and socio-economic issues, and the long-term commitment from all partners based on a shared vision and clearly defined objectives.

Period of consultation

From 11.07.2012 to 04.10.2012

contribution.


- If you are answering this consultation on behalf of a **public authority**, please [click here](#) to submit your contribution.

Contributions will be published on the Internet. It is important to read the specific privacy statement

YOU CAN CONTRIBUTE!

Last remarks (i)

- Strategy



- Suport

- NCPs, IMI Executive Office, support offices, Plat. Med. Inn., Asebio, Nanomed, etc.



CDTI - Contact details

CDTI	Contact Person	E-mail
Dpto. Progr. Marco de I+D. Dir. Programas Innovadores Globales	Marta Gómez Quintanilla Representante Salud e IMI	marta.gomez@cdti.es
Dpto. Biotecnología, Salud y Agroalimentación. Dirección Mercados Innovadores Globales	Carolina Carrasco NCP- HEALTH	carolina.carrasco@cdti.es
	Pilar Sanz	mariapilar.sanz@cdti.es
	M ^a Pilar de Miguel NCP-NMP	mariapilar.demiguel@cdti.es




www.cdti.es
915815500



www.cdti.es/pidi
902347434

LINKS



Mailing List

www.imi.europa.eu

www.cdti.es

Agenda

Info FP7 & IMI



3rd Call for proposals is launched

IMI has launched the 3rd Call for proposals. If you wish to take part in an IMI project, read the detailed topic descriptions and the information necessary to submit an Expression of Interest. [more](#)

ABOUT IMI



The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

EVENTS

Webinars 3rd Call topics IMI organises a series of webinars about the topics of the 3rd Call, featuring the same presenters and presentations as during the workshops of the Open Info Day of 22 October 2010. The webinars are scheduled in October and November 2010.

RECENT WEB UPDATES

- New services and information have been added
- New IP Guidelines are available
- 3rd Call is launched
- Upcoming webinars 3rd Call
- Find 3rd Call Partners
- IMI Newsletter
- Call for tenders

IMI NEWSFLASH

29/11/2010 : IMI's 3rd webinar on personalized medicine in diabetes treatment is today 14:00-15:00! It part opens follow instructions: <http://bit.ly/OCHeKX>

19/11/2010 : IMI's webinar on human resources in innovation is

Last remarks (ii)

Opportunity rarely knocks on your door.
Knock rather on opportunity's door if you
ardently wish to enter.

B. C. Forbes

Good luck!





Marta Gómez Quintanilla

Spanish Representative - HEALTH

Spanish Representative - IMI

Spanish MB Member - JPND

Ph: 34 91 581 55 62 / 00

[marta.gomez\[at\]cdti.es](mailto:marta.gomez[at]cdti.es) - www.cdti.es